# Coridea

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/coridea

- Industry: Business Support Services
- Headquarters: New York, US
- Website: www.coridea.com
- Latest round: Seed (Jun 1, 2010)
- Investors on record: 1

## About

Coridea Inc. is a company that focuses on the development and commercialization of innovative medical technologies designed to enhance patient outcomes through minimally invasive surgical instruments and therapeutic devices.Coridea Inc. was founded in 2003 and is headquartered in New York, US. The company specializes in creating medical solutions aimed at improving surgical precision and recovery times for patients. The founders, Louisa T and Mark Gelfand, established the firm with a vision to transform healthcare technology. Coridea received Seed financing from SV Life Sciences in June 2010, marking its first funding round.Coridea specializes in developing and commercializing innovative medical technologies aimed at improving patient outcomes. The company focuses on creating high-impact solutions that span surgical instruments and therapeutic devices designed for minimally invasive procedures. These products target a variety of medical fields, addressing needs such as enhanced surgical precision and reduced recovery times for patients. Coridea's offerings are designed to serve healthcare providers, including hospitals and outpatient surgical centers, as well as a diverse range of end-users who benefit from improved medical treatments. The company operates primarily in North America and Europe, where its products are integrated into various healthcare systems to optimize patient care.Coridea's revenue model is structured around direct sales and partnerships with healthcare providers and institutions. The company engages in business transactions primarily through B2B channels, supplying hospitals and clinics with its proprietary medical devices and services. Revenue is generated by selling specific products, which may include flagship offerings known for their innovative designs and effectiveness in clinical settings. Clients typically engage in purchase agreements, facilitating a steady flow of transactions as healthcare providers integrate Coridea's solutions into their operations. The company’s financial performance is bolstered by its ability to secure significant NIH grants, which further supports its research and development initiatives.Looking ahead, Coridea plans to launch new products that are currently in the design phase, aiming for a release within the next two years. The company is also targeting expansion into additional European markets, with a goal to establish a presence by the end of 2024. The funding obtained from the Seed financing in 2010 will be utilized to support these product developments and market entry strategies.

## Funding rounds

- Seed, Jun 1, 2010 — SV Health Investors

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Seed